Nav-ACNES: Sodium Channel Mutations in Patient With the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)

Sponsor
Maxima Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05877274
Collaborator
(none)
50
1
6
8.3

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about sodium channel (Nav) mutations in patients with the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES). This study will give more insight into the pathophysiology of ACNES, which is still largely unknown.

The primary objective is to determine if there are mutations of Nav1.7 and Nav1.8 in patients with ACNES. Therefore, one blood sample will be drawn, in which the mutations will be analyzed.

Condition or Disease Intervention/Treatment Phase
  • Other: Sodium channel mutation

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Sodium Channel Mutations (SCN9A, SCN10A) in the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients with ACNES

Patients with ACNES who fulfill the inclusion criteria.

Other: Sodium channel mutation
Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.

Outcome Measures

Primary Outcome Measures

  1. Sodium Channel 1.7 and 1.8 mutation. [Blood samples for SCN analysis will be taken only once after obtaining informed consent. This is the start of the study. Outpatient discharge (free of pain or no treatment options) is end of study. Treatment period can be a couple of weeks or months.]

    Number of SCN9A and SCN10A mutations. Each mutation will be classified following one of three classes; unknown pathogenicity, probable pathogenicity, and pathogen variant.

Secondary Outcome Measures

  1. Correlation between mutations and known cause of ACNES. [Baseline data will be obtained during first outpatient visit, before start of the treatment. The first outpatient visit takes 30 minutes (standard of care).]

    Patients are asked (standard of care) if there is a possible cause of the ACNES. Correlations between the causes of ACNES and any identified mutations will be examined.

  2. Correlation between mutations and pain score at start of treatment. [Baseline data will be obtained during first outpatient visit, before start of the treatment. The first outpatient visit takes 30 minutes (standard of care).]

    Patients are asked (standard of care) about the average pain score following the 0-10 numeric rating scale (NRS) (0 = no pain, 10 worst possible pain). Correlations between the NRS pain score and found mutations will be examined.

  3. Correlation between mutations and treatment response. [Treatment response will be assessed after each treatment during the treatment period at our outpatient clinic, up to 6 weeks after treatment.]

    Patients follow different treatments according standard of care for ACNES. Starting with trigger point injections with a local anesthetic, if this treatment is not sufficient, it is followed by Pulse Radiofrequency. When patients still experience pain after minimal invasive treatments, a surgical neurectomy is performed. Correlations between treatment outcome after the different treatment options and found mutations will be examined. Treatment is defined successful if the patient does not need additional treatment, has >50% pain reduction, or reduction of >4 NRS points.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

In order to be eligible to participate in this study, a subject must be diagnosed with ACNES and receive treatment at our outpatient clinic. Additionally, subject has to meet one of the following criteria:

  • Known to have a first- or second-degree relative with ACNES;

  • Have more than one recurrence of ACNES after a pain free period or ACNES at multiple locations in the abdominal wall;

  • Persistent pain after posterior neurectomy.

Exclusion Criteria:
  • Inability to understand Dutch language.

  • Known neuromuscular or neurodegenerative disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maxima Medical Center Veldhoven Netherlands 5504 DB

Sponsors and Collaborators

  • Maxima Medical Center

Investigators

  • Principal Investigator: Rudi Roumen, MD, PhD, Maxima Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
dr. RMH Roumen, surgeon, Head of surgery, Principal Investigator, Maxima Medical Center
ClinicalTrials.gov Identifier:
NCT05877274
Other Study ID Numbers:
  • NL84021.015.23
First Posted:
May 26, 2023
Last Update Posted:
May 31, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by dr. RMH Roumen, surgeon, Head of surgery, Principal Investigator, Maxima Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 31, 2023